Literature DB >> 9199476

Murine antibody responses to the verotoxin 1 B subunit: demonstration of major histocompatibility complex dependence and an immunodominant epitope involving phenylalanine 30.

D J Bast1, J Sandhu, N Hozumi, B Barber, J Brunton.   

Abstract

Structurally conserved verotoxin 1 (VT1) mutant derivatives, showing reduced receptor binding and cytotoxicity, may serve as natural toxoids to protect against VT-mediated disease. In this study, the antibody responses to the wild-type VT1 B subunit, a B-subunit mutant (Phe30Ala B), and the corresponding holotoxin (Phe30Ala HT) were examined in three inbred mouse strains. BALB/c (H-2d) and CBA (H-2k) mice produced strong antibody responses to both wild-type and mutant B subunits. VT1 B-raised sera reacted more strongly with VT1 B than with Phe30Ala B in enzyme-linked immunosorbent assays, while Phe30Ala B-raised sera reacted equally with VT1 B and Phe30Ala B. C57BL/6 (H-2b) and congenic BALB/c (BALB x B [H-2b]) mice produced no detectable antibody response to either VT1 B or Phe30Ala B. However, an anti-VT1 B antibody response was detected in H-2b mice immunized with biologically active Phe30Ala HT. Based on these observations, we conclude that the VT1 B subunit possesses a B-cell immunodominant epitope formed partly by phenylalanine 30 and that the B-subunit antibody response is dependent on the H-2 haplotype of the mouse strain. Our results also support a potential role for the A subunit in providing the T-cell help necessary to overcome a deficient B-subunit antibody response in H-2b mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9199476      PMCID: PMC175418          DOI: 10.1128/iai.65.7.2978-2982.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

Authors:  Y Endo; K Tsurugi; T Yutsudo; Y Takeda; T Ogasawara; K Igarashi
Journal:  Eur J Biochem       Date:  1988-01-15

2.  Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR.

Authors:  D W Acheson; M M Levine; J B Kaper; G T Keusch
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

3.  Toxicity and immunogenicity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits.

Authors:  D J Bast; J L Brunton; M A Karmali; S E Richardson
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

4.  The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections.

Authors:  S E Richardson; M A Karmali; L E Becker; C R Smith
Journal:  Hum Pathol       Date:  1988-09       Impact factor: 3.466

5.  Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2.

Authors:  S M Scotland; G A Willshaw; H R Smith; B Rowe
Journal:  Epidemiol Infect       Date:  1987-12       Impact factor: 2.451

6.  Phenylalanine 30 plays an important role in receptor binding of verotoxin-1.

Authors:  C Clark; D Bast; A M Sharp; P M St Hilaire; R Agha; P E Stein; E J Toone; R J Read; J L Brunton
Journal:  Mol Microbiol       Date:  1996-02       Impact factor: 3.501

7.  Genetic control of the murine immune response to cholera toxin.

Authors:  C O Elson; W Ealding
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

Review 8.  Infection by verocytotoxin-producing Escherichia coli.

Authors:  M A Karmali
Journal:  Clin Microbiol Rev       Date:  1989-01       Impact factor: 26.132

9.  Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1.

Authors:  K Sandvig; S Olsnes; J E Brown; O W Petersen; B van Deurs
Journal:  J Cell Biol       Date:  1989-04       Impact factor: 10.539

10.  A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit.

Authors:  M Pizza; M R Fontana; M M Giuliani; M Domenighini; C Magagnoli; V Giannelli; D Nucci; W Hol; R Manetti; R Rappuoli
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  6 in total

1.  Development of recombinant B subunit of Shiga-like toxin 1 as a probe to detect carbohydrate ligands in immunochemical and flowcytometric application.

Authors:  S Miyashita; Y Matsuura; D Miyamoto; Y Suzuki; Y Imai
Journal:  Glycoconj J       Date:  1999-11       Impact factor: 2.916

2.  Antiviral activity of shiga toxin 1: suppression of bovine leukemia virus-related spontaneous lymphocyte proliferation.

Authors:  W A Ferens; C J Hovde
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

3.  Mouse toxicity and cytokine release by verotoxin 1 B subunit mutants.

Authors:  V M Wolski; A M Soltyk; J L Brunton
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

4.  Production of secretory immunoglobulin A against Shiga toxin-binding subunits in mice by mucosal immunization.

Authors:  Yasuyuki Imai; Rio Nagai; Yousuke Ono; Tomoyuki Ishikawa; Hiroki Nakagami; Takashi Tanikawa; Kohta Kurohane
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

Review 5.  Verotoxin-1 treatment or manipulation of its receptor globotriaosylceramide (gb3) for reversal of multidrug resistance to cancer chemotherapy.

Authors:  Parviz Behnam-Motlagh; Andreas Tyler; Kjell Grankvist; Anders Johansson
Journal:  Toxins (Basel)       Date:  2010-10-25       Impact factor: 4.546

Review 6.  Shiga Toxins as Antitumor Tools.

Authors:  Aude Robert; Joëlle Wiels
Journal:  Toxins (Basel)       Date:  2021-09-28       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.